MARIPOSA

Question 1

when and where was MARIPOSA published

Answer 1

June 26, 2024 in the New England Journal of Medicine

Question 2

what is the Title of MARIPOSA

Answer 2

Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated (exon 19 deletions and exon 21 L858R mutations) Advanced NSCLC

Question 3

what was the Study Design of MARIPOSA

Answer 3

• phase 3
• international
• randomized

Question 4

what were the comparators in MARIPOSA

Answer 4

• Amivantamab + Lazertinib vs. Osimertinib

Question 5

what is Amivantamab

Answer 5

EGFR-MET bispecific antibody with immune cell-directing activity that targets activating and resistance EGFR mutations and MET mutations and amplifications

Question 6

what is Lazertinib

Answer 6

3rd generation EGFR TKI

Question 7

what is Osimertinib

Answer 7

3rd generation EGFR TKI and standard of care in EGFR NSCLC

Question 8

what is the primary endpoint

Answer 8

PFS (progression free survival) in the Ami/ Laz group vs. the Osi grp

Question 9

how many patients were in the study

Answer 9

• 1074 total
• 429 Ami/ Laz
• 429 Osi
• 216 Laz

Question 10

what was PFS for each group studied

Answer 10

• Ami/ Laz: 23.7 mo.
• Osi: 16.6

Question 11

what was the ORR for each group

Answer 11

• Ami/ Laz: 86%
• Osi: 85%

Question 12

what was the CRR

Answer 12

• Ami/ Laz: 336
• Osi: 314

Question 13

what was the MDOR

Answer 13

• Ami/ Laz: 25.8 mo.
• Osi: 16.8 mo.

Question 14

what was the incidence of discontinuation of all agents due to treatment adverse events

Answer 14

• Ami/ Laz: 10%
• Osi: 3%